Clinical trials: Advance Solid Tumors
Advanced Malignant Solid Neoplasm, Malignant Brain Neoplasm
Educational Tools for the Improvement of Early Advance Care Planning in Adolescents and Young Adults With Advanced Solid Tumors and High-Grade Brain Tumors
This clinical trial studies whether educational tools work to improve early advance care planning (ACP) in adolescents and young adults (AYAs) with solid tumors that may have spread from where they first started to nearby tissue…
- Conditions
- Advanced Malignant Solid Neoplasm, Malignant Brain Neoplasm, Recurrent Advanced Malignant Solid Neoplasm
- Trial name
- NCT07174661
- Testing
- Advance Care Planning, Educational Intervention, Electronic Health Record Review
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Mayo Clinic
Cancer
A Phase I Study to Investigate the Safety, Tolerability and Pharmacokinetic Profile of of GSK2118436 in Japanese Subjects With BRAF Mutation Positive Solid Tumors
BRF116056 is the first clinical experience with GSK2118436, a BRAF inhibitor, in Japan. This study will be designed to assess safety, tolerability, single and repeat dose PK profile and preliminary efficacy of GSK2118436 in…
- Trial name
- NCT01582997
- Testing
- GSK2118436
- Where
- 2 sites in Japan
- Volunteers
- 12 people
- Sponsor
- GlaxoSmithKline
Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphatic System Neoplasm
Telephone-Based Coaching Sessions (TAC) to Improve Advance Care Planning Participation in Advanced Cancer Patients and Their Support Person
This clinical trial studies whether telephone-based coaching sessions, Talking About Cancer (TAC), work to improve engagement in advance care planning (ACP) in patients with cancer that may have spread from where it first started…
- Trial name
- NCT07141407
- Testing
- Supportive Care, Telephone-Based Intervention, Survey Administration
- Where
- 3 sites in United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Fred Hutchinson Cancer Center
Advanced Solid Tumor
Study of LM-302 in Patients With Advance Solid Tumors
A Phase I/II Study of LM-302 in Patients with CLDN18.2-Positive Advanced Solid Tumors
- Trial name
- NCT05161390
- Testing
- LM-302 Injection
- Where
- China
- Volunteers
- 153 people
- Sponsor
- LaNova Medicines Zhejiang Co., Ltd.
Advanced Non-Hematologic Malignancies
CP-751,871 In Combination With Docetaxel In Advance Non-hematologic Malignancies
This clinical trial is designed to determine the safety, tolerability, pharmacokinetics and pharmacodynamic effects of escalating doses of CP 751,871 given in combination with docetaxel in patients with non-hematologic…
- Trial name
- NCT01653158
- Testing
- CP-751,871, Docetaxel
- Where
- United Kingdom
- Volunteers
- 46 people
- Sponsor
- Pfizer
Advanced Solid Tumor
Study of LM-102 in Patients With Advance Solid Tumors
This is an open label Phase I/II trial of LM-102 injection, a recombinant humanized monoclonal antibody targeting Claudin 18.2 (CLDN18.2).
- Trial name
- NCT05008445
- Testing
- LM-102 Injection, LM-102 Injection combined with SOC
- Where
- China
- Volunteers
- 11 people
- Sponsor
- LaNova Medicines Development Co., Ltd.
COPD, Severe or Very Severe Airflow Obstruction and/or Receiving or Eligible to Receive Long-term Oxygen Therapy
Study of Default Options in Advance Directives
Default options represent the events or conditions that are set into place if no alternatives are actively chosen. The setting of default options has well-established effects on a broad range of human decisions, but its influence…
- Conditions
- COPD, Severe or Very Severe Airflow Obstruction and/or Receiving or Eligible to Receive Long-term Oxygen Therapy, Idiopathic Pulmonary Fibrosis, Other Interstitial Lung Disease Without Curative Therapy
- Trial name
- NCT01817686
- Testing
- Comfort Default AD forms, Life Extension Default AD forms, Standard Default AD forms
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- Corporal Michael J. Crescenz VA Medical Center
Advanced Solid Tumors
A Phase I Study of TAS-102 in Patients With Advanced Solid Tumors With Renal Impairment
Study to evaluate the safety, tolerability, and pharmacokinetics of TAS-102 in patients with advanced solid tumors and varying degrees of renal impairment.
- Trial name
- NCT02301117
- Testing
- TAS-102
- Where
- 14 sites in United States, Czechia and 1 more
- Volunteers
- 43 people
- Sponsor
- Taiho Oncology, Inc.
Ovarian, Melanoma
Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-PP) for Patients With Advanced Cancer.
The present clinical trial is a dose comparison of a multi-component active immunotherapy designed to stimulate an immune reaction to specific tumor associated antigens which are highly expressed on a large number of solid…
- Conditions
- Ovarian, Melanoma, Renal, Prostate
- Trial name
- NCT00423254
- Testing
- PSMA/PRAME
- Where
- 5 sites in United States
- Volunteers
- 12 people
- Sponsor
- Mannkind Corporation
Hematopoietic and Lymphoid Cell Neoplasm, Immune System Disorder
Collection of Research Data and Samples From Patients Treated With Immunotherapy to Study Its Side Effects
This study collects research data and samples from patients who experience immunotherapy side effects to store for use in future research studies.
- Conditions
- Hematopoietic and Lymphoid Cell Neoplasm, Immune System Disorder, Malignant Solid Neoplasm
- Trial name
- NCT04242095
- Testing
- Biospecimen Collection, Medical Chart Review
- Where
- 629 sites in United States
- Volunteers
- 2,240 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Advanced Malignancies, Solid Tumors
Pharmacokinetics of Patupilone After a Single Intravenous Administration in Patients With Advance Solid Tumor Malignancies.
The main purpose of this study is to characterize the distribution, metabolism, and elimination (ADME) of Patupilone after a single intravenous administration in patients with advanced solid tumor malignancies
- Trial name
- NCT00426140
- Testing
- Patupilone
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Novartis Pharmaceuticals
Solid Tumors
A Study of Tor Kinase Inhibitor in Advanced Tumors
The purpose of the study is to assess the safety, tolerability and pharmacokinetics of AZD8055 and determine the maximum tolerated dose to take into phase II trials.
- Trial name
- NCT00731263
- Testing
- AZD8055
- Where
- 4 sites in United States, France and 1 more
- Volunteers
- 64 people
- Sponsor
- AstraZeneca
Advanced Solid Tumor
Phase 1/2 Study of Intratumoral Injection of STX-001 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab
Phase 1/2, Open-label, Multi-center, First-in-human Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of STX-001 Delivered by Intratumoral Injection in Patients with Advanced Solid…
- Trial name
- NCT06249048
- Testing
- STX-001, Keytruda®
- Where
- 7 sites in United States, Australia
- Volunteers
- 108 people
- Sponsor
- Strand Therapeutics Inc.
Solid Tumors
ODM-207 in Patients With Advance Solid Tumours
This is a first-in-man study to assess the safety and tolerability and to characterise the pharmacokinetics of ODM-207.
- Trial name
- BETIDES (NCT03035591)
- Testing
- ODM-207
- Where
- Finland
- Volunteers
- 36 people
- Sponsor
- Orion Corporation, Orion Pharma
Advanced Solid Malignancies
10mg ZD4054 (Zibotentan) PK Study in Male, Elderly Chinese Patients With Advanced Solid Malignancies
The purpose of this study is to assess the pharmacokinetics of single and multiple doses of 10mg ZD4054 (Zibotentan) in male, elderly Chinese patients with advanced solid malignancies.
- Trial name
- NCT00997945
- Testing
- ZD4054 (Zibotentan)
- Where
- China
- Volunteers
- 15 people
- Sponsor
- AstraZeneca
Leukemia, Multiple Mieloma
The Implementation of the Go Wish Game to Promote Advance Care Planning in Onco- Hematologic Disease
This is a mixed-method, device-free and drug-free multicenter interventional study. The study aims at facilitating end-of-life conversations within the doctor-patient relationship through the use of the Go Wish Game (GWG) and…
- Conditions
- Leukemia, Multiple Mieloma, Advanced Solid Tumors, Lymphoma
- Trial name
- OHGW-ACP (NCT06795815)
- Testing
- Go Wish Game
- Where
- Italy
- Volunteers
- 75 people
- Sponsor
- Azienda USL Reggio Emilia - IRCCS
Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm
PLAN Intervention to Enhance Engagement of Latino Cancer Patients in Advanced Care Planning
This trial tests whether Planning for Your Advance Care Needs (PLAN) intervention works to enhance Latino patients' understanding of and engagement in advanced care planning.
- Trial name
- NCT04889144
- Testing
- Communication Intervention, Best Practice, Questionnaire Administration
- Where
- 4 sites in United States
- Volunteers
- 27 people
- Sponsor
- Fred Hutchinson Cancer Center
Advance Solid Tumors, Advanced Malignant Solid Tumors
A Study of CS231295 in Patients With Advanced Solid Tumors
This is a Phase I, single-arm, open-label, dose-escalation, multicenter clinical study of CS231295 in patients with advanced solid malignant tumors.
- Trial name
- NCT07612488
- Testing
- a small molecular multi-target kinase inhibitor
- Where
- 4 sites in United States
- Volunteers
- 42 people
- Sponsor
- ThalassaX Therapeutics United States Ltd
Advance Solid Tumors, Lymphoma, Non-Hodgkin
Study of JMBI-001 in Patients With MYC-Positive Advanced Cancers
Evaluate the safety and tolerability of JMBI-001 in adults with MYC-positive advanced cancers.
- Trial name
- PANGU-1 (NCT07864701)
- Testing
- JMBI-001 Tablets
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Chengdu Anticancer Bioscience, Ltd.